Disc Medicine Inc. (IRON) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Disc Medicine Inc. (IRON) has a cash flow conversion efficiency ratio of -0.090x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-62.24 Million) by net assets ($688.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check IRON capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Disc Medicine Inc. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Disc Medicine Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. See IRON net asset value for net asset value and shareholders' equity analysis.
Disc Medicine Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Disc Medicine Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Amot Investments Ltd
TA:AMOT
|
0.024x |
|
Beijing Venustech Inc
SHE:002439
|
0.005x |
|
AIMA Technology Group Co Ltd
SHG:603529
|
0.294x |
|
Clas Ohlson AB (publ)
ST:CLAS-B
|
0.515x |
|
Zhuzhou CRRC Times Electric Co. Ltd
F:ZTX
|
0.069x |
|
YAMAHA CORP.SP.ADR/1 O.N.
F:YHAA
|
N/A |
|
Thule Group AB
ST:THULE
|
0.007x |
|
Boise Cascad Llc
NYSE:BCC
|
0.055x |
Annual Cash Flow Conversion Efficiency for Disc Medicine Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Disc Medicine Inc. from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Disc Medicine Inc. worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $739.83 Million | $-180.39 Million | -0.244x | -15.16% |
| 2024-12-31 | $443.59 Million | $-93.93 Million | -0.212x | +0.52% |
| 2023-12-31 | $345.12 Million | $-73.46 Million | -0.213x | +11.03% |
| 2022-12-31 | $176.60 Million | $-42.25 Million | -0.239x | -155.79% |
| 2021-12-31 | $-64.20 Million | $-27.53 Million | 0.429x | -71.34% |
| 2020-12-31 | $-21.86 Million | $-32.71 Million | 1.496x | -- |
About Disc Medicine Inc.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associ… Read more